Invitrogen is a provider of essential life science technologies for research, production and diagnostics. This will be the company's first stock split since it went public on the NASDAQ Exchange in 1999.

About Invitrogen

Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.

Safe Harbor Statement

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to; 1) Invitrogen is well positioned to capitalize on growth opportunities. Potential risks and uncertainties include, but are not limited to a) Invitrogen may or may not be able to execute against its strategy; as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.

SOURCE: Invitrogen Corporation

Invitrogen Corporation
Amanda Clardy, VP, Investor Relations, 760-603-7200

Separately, Sequenom announced the sale of its first MassARRAY system in South America. The system was sold to a sugarcane consortium to be used in biofuel research and development. Sequenom's technology will be used as part of an effort to engineer an even more productive line of sugarcane for ethanol production.

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com

Knobias.com, LLC
601-978-3399
601-978-3675
info@knobias.com
www.knobias.com/cmtx

Here is a synopsis of today's Zacks Rank Buy Stocks:

Aggressive Growth - Invitrogen Corporation (Nasdaq: IVGN)

Invitrogen Corporation, which recently approved a two-for-one stock split, is trading near a 52-week high after reporting a robust first quarter. Earnings per share increased by 36% year-over-year and revenues grew by 13.5% rise in revenues over the same time period. Wall Street estimates have been climbing higher. All 13 covering analysts upped last month's full-year 2008 forecasts of $4.53 per share to $4.80, and one analyst further increased the projection by a penny.

Zacks Guide to Aggressive Growth Investing (free!): http://at.zacks.com/?id=4309

Growth & Income - Mastercard Incorporated (NYSE: MA)

Mastercard Incorporated is Zacks #1 (Strong Buy) company that is trading near a 52-week high after announcing an outstanding first quarter. Wall Street responded to the company's stellar results buy hiking earnings forecasts. Mastercard's ROE of 27% is nearly double the industry's average of 14%. MA's net profit margin of 26.7% crushes the industry's average of 4.8%.

Zacks Guide to Growth & Income Investing (free!): http://at.zacks.com/?id=4310

Momentum - Celanese Corp. (NYSE: CE)

Celanese Corp. is a company on the upswing. It just reported solid first quarter results on Apr 24 that included sales growth of 19% from the year before. This translated into adjusted earnings of $1.06 per share, well ahead of analyst expectations. Moving forward, Celanese said it anticipates strong international demand and continued pricing strength, which should help fuel the underlying data to support its share price.

Zacks Guide to Momentum Investing (free!): http://at.zacks.com/?id=4311

Value - Olympic Steel Inc. (Nasdaq: ZEUS)

Olympic Steel capitalized on rising commodity prices and strong demand for processed steel to post record first-quarter earnings results. The company beat Wall Street estimates by 24.74%. Olympic Steel has a forward P/E of 13.28.

Zacks Guide to Value Investing (free!): http://at.zacks.com/?id=4312

The free special report, "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions," provides an insightful background about this wealth-building tool. Download your free copy of the report now to prosper in the years to come by visiting http://at.zacks.com/?id=93.

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988, #1 Rank stocks have generated an average annual return of +32.2%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained +43.8%, while the S&P 500 tumbled -37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have underperformed the S&P 500 by 129% annually (+5.3% vs. +12.1%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of Zacks Rank Buy stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=90.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros http://at.zacks.com/?id=91

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com
Aggressive Growth Stocks:
Contact: Roopak Chakravarty
Phone: 312-265-9188
or
Growth & Income Stocks:
Contact: Alex Kolb
Phone: 312-265-9149
or
Momentum Stocks:
Contact: Michael Vodicka
Phone: 312-265-9226
or
Value Stocks:
Contact: Tracey Ryniec
Phone: 312-265-9232
Email: pr@zacks.com
Visit: www.zacks.com

Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Stock Split The company recently approved its first two-for-one stock split. Invitrogen noted that it established May 16, 2008, as the record date and May 27, 2008, as the date on which additional shares will be distributed to shareholders.

'Today's decision by the Board of Directors reflects the company's strong financial performance and confidence in our long-term strategy,' said Greg Lucier, Invitrogen's Chairman and Chief Executive Officer. 'The end markets for our technologies are solid, and we remain well positioned to capitalize on the growth opportunities we see in the future.'

Strong First Quarter The company's share price received a nice boost after the release of first-quarter results last week, and is now trading near a 52-week high. The quarterly report boasted robust growth, which included a 36% year-over-year increase in earnings per share and a 13.5% rise in revenues over the same time period.

Bullish Forecasts Wall Street estimates have been climbing higher. All 13 covering analysts upped last month's full-year 2008 forecasts of $4.53 per share to $4.80, and one analyst further increased the projection by a penny. The company's return on equity (ROE) of 13% stands well above the industry average of 8%.

Zacks #1 Ranked Stocks have generated an average annual return of 31.8% since 1988. Every day we highlight four new Zacks Rank Buy stocks on the Zacks.com home page. Discover the Four Stocks we are Recommending Now!